The Journal of Internal Korean Medicine (대한한방내과학회지)

The Society of Internal Korean Medicine (대한한방내과학회)
권호 표지
DOI QR코드

DOI QR Code

Case Report of Metabolic Dysfunction-Associated Fatty Liver Disease Treated with Saenggangunbi-tang

대사이상 관련 지방간질환의 생간건비탕 치험 1례

  • Cho Hyun Hwang (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University) ;
  • Juyoung Lee (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University) ;
  • Eunkyung Lee (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University) ;
  • Eungyeong Jang (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University) ;
  • Youngchul Kim (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University) ;
  • Jang-Hoon Lee (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University)
  • 황조현 (경희대학교 한의과대학 간계내과학교실) ;
  • 이주영 (경희대학교 한의과대학 간계내과학교실) ;
  • 이은경 (경희대학교 한의과대학 간계내과학교실) ;
  • 장은경 (경희대학교 한의과대학 간계내과학교실) ;
  • 김영철 (경희대학교 한의과대학 간계내과학교실) ;
  • 이장훈 (경희대학교 한의과대학 간계내과학교실)
  • Received : 2023.04.06
  • Accepted : 2023.05.25
  • Published : 2023.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: This study identified the effects of Korean medicine treatment on a patient with metabolic dysfunction-associated fatty liver disease (MAFLD). Methods: A 43-year-old man with MAFLD was treated with Saenggangunbi-tang with regular exercise from August 13, 2022, to December 24, 2022, to reduce fatigue and dyspepsia and to improve laboratory findings, such as liver enzymes and lipid profiles. We observed changes in symptoms and laboratory findings during the approximately four-month treatment. Results: Treatment with Saenggangunbi-tang resulted in decreased serum levels of liver enzymes, triglycerides, hepatic steatosis index scores, and clinical symptoms. During the treatment, the patient performed regular exercise; however, there was no significant change in body weight until the end of the study. Conclusion: This study suggests the availability of Saenggangunbi-tang as a therapeutic option for managing MAFLD patients.

Keywords

References

  1. Rui F, Yang H, Hu X, Xue Q, Cu Y, Shi J, et al. Renaming NAFLD to MAFLD: Advantages and Potential Changes in Diagnosis, Pathophysiology, Treatment, and Management. Infectious Microbes & Diseases 2022;4(2):49-55. https://doi.org/10.1097/IM9.0000000000000089
  2. Eslam M, Newsome P, Sarin S, Anstee Q, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus state. J Hepatol 2020;73(1):202-9. https://doi.org/10.1016/j.jhep.2020.03.039
  3. Stefan N, Haring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet 2019;7(4):313-24. https://doi.org/10.1016/S2213-8587(18)30154-2
  4. Yin X, Guo X, Liu Z, Wang J. Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2023;24(3):1-23. https://doi.org/10.3390/ijms24032844
  5. Rojas A, Lara-Romero C, Munoz-Hernandez R, Gato S, Ampuero J, Romero-Gomez M. Emerging pharmacological treatment options of MAFLD. Ther Adv Endocrinol Metab 2022:13:1-15. https://doi.org/10.1177/20420188221142452
  6. Lee YR, Cho NK, Choi HS, Kim SM, Kim KS. A systematic review of Korean medicine for non-alcoholic fatty liver disease. J Int Korean Med 2019;40(1):13-37. https://doi.org/10.22246/jikm.2019.40.1.13
  7. Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010;42(7):503-8. https://doi.org/10.1016/j.dld.2009.08.002
  8. Kim MY. The diagnosis of nonalcoholic fatty liver disease. Korean J Med 2014;86(4):405-15. https://doi.org/10.3904/kjm.2014.86.4.405
  9. Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. Clin Gastroenterol and Hepatol 2021;19(10):2172-81. https://doi.org/10.1016/j.cgh.2021.05.029
  10. Eslam M, Sanyal A, George J. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterol 2020;150(7):1999-2014. https://doi.org/10.1053/j.gastro.2019.11.312
  11. Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. Am J Roentgenol 2007;189(6):320-3. https://doi.org/10.2214/AJR.07.2123
  12. Nakatsuka T, Tateishi R, Koike K. Changing clinical management of NAFLD in Asia. Liver Int 2022;42(9):1955-68. https://doi.org/10.1111/liv.15046
  13. van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008;48(2):449-57. https://doi.org/10.1002/hep.22350
  14. Woo HJ, Lee JH, Kim YC, Kim GS, Son CK, Jo JH, et al. Oriental Internal Medicine on Hepatobiliary System, Hematology and Toxicology. 6th edition. Seoul: Nado; 2016, p. 307-15.
  15. Kim EJ, Hwang CH, Lee JY, Jang EG, Kim YC, Lee JH. A case report of nonalcoholic fatty liver disease with obesity and dyslipidemia. J Int Korean Med 2022;43(2):184-90. https://doi.org/10.22246/jikm.2022.43.2.184
  16. Kim HY, Joo SH, Bae JH, Jang EG, Kim YC, Lee JH. A case report of nonalcoholic steatohepatitis with metabolic syndrome. J Int Korean Med 2017;38(2):125-30. https://doi.org/10.22246/jikm.2017.38.2.125
  17. Tomizawa M, Kawanabe Y, Shinozaki F, Sato S, Motoyoshi Y, Sugiyama T, et al. Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes. Biomed Rep 2014;2(5):633-6. https://doi.org/10.3892/br.2014.309
  18. Nengguang F, Peng L, Xia Z, Zhang L, Song Z, Wang Y, et al. Triglycerides to high-density lipoprotein cholesterol ratio as a surrogate for nonalcoholic fatty liver disease: a cross-sectional study. Lipids Health Dis 2019;18(39):1-6. https://doi.org/10.1186/s12944-018-0950-y
  19. Park SH, Kim BI, Yun JW, Kim JW, Park DI, Cho YK, et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol 2004;19(6):694-8. https://doi.org/10.1111/j.1440-1746.2004.03362.x
  20. Jung YW, Kim M, Kim BK, Park JY, Kim DY, Ahn SH, et al. Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B. J Korean Med Sci 2020;35(17):1-11. https://doi.org/10.3904/kjim.2019.317